GSK's new once-daily inhaled fluticasone product worked in Phase 2 trial (RCT, Thorax)
www.pulmccm.org
GlaxoSmithKline has a new once-daily inhaled corticosteroid called fluticasone furoate; it has enhanced affinity for glucocorticoid receptors and a longer duration of action compared to the commonly-used fluticasone propionate, which must be taken twice daily to achieve a steady bioavailable concentration.
GSK's new once-daily inhaled fluticasone product worked in Phase 2 trial (RCT, Thorax)
GSK's new once-daily inhaled fluticasone…
GSK's new once-daily inhaled fluticasone product worked in Phase 2 trial (RCT, Thorax)
GlaxoSmithKline has a new once-daily inhaled corticosteroid called fluticasone furoate; it has enhanced affinity for glucocorticoid receptors and a longer duration of action compared to the commonly-used fluticasone propionate, which must be taken twice daily to achieve a steady bioavailable concentration.